Order Article Reprints

Abu Shtaya A, Kedar I, Mattar S, Mahamid A, Basel-Salmon L, Farage Barhom S, Naftaly Nathan S, Magal N, Azulay N, Levy Zalcberg M, et al. The Diagnostic Yield and Implications of Targeted Founder Pathogenic Variant Testing in an Israeli Cohort. Cancers. 2024; 16(1):94. https://doi.org/10.3390/cancers16010094

Abu Shtaya, Aasem, Inbal Kedar, Samar Mattar, Ahmad Mahamid, Lina Basel-Salmon, Sarit Farage Barhom, Sofia Naftaly Nathan, Nurit Magal, Noy Azulay, Michal Levy Zalcberg, and et al. 2024. "The Diagnostic Yield and Implications of Targeted Founder Pathogenic Variant Testing in an Israeli Cohort" Cancers 16, no. 1: 94. https://doi.org/10.3390/cancers16010094

Abu Shtaya, A., Kedar, I., Mattar, S., Mahamid, A., Basel-Salmon, L., Farage Barhom, S., Naftaly Nathan, S., Magal, N., Azulay, N., Levy Zalcberg, M., Chen-Shtoyerman, R., Segol, O., Seri, M., Reznick Levi, G., Shkedi-Rafid, S., Vinkler, C., Netzer, I., Hagari Bechar, O., Chamma, L., ... Goldberg, Y. (2024). The Diagnostic Yield and Implications of Targeted Founder Pathogenic Variant Testing in an Israeli Cohort. Cancers, 16(1), 94. https://doi.org/10.3390/cancers16010094